Age | | | | |
<6 months | 9 | 5 (56) | | |
⩾6 months | 35 | 12 (34) | 0.25 (0.09 to 1.85) | 0.25 |
<22 months | 25 | 11 (44) | | |
⩾22 months | 19 | 6 (32) | 0.59 (0.17 to 2.05) | 0.40 |
Sex | | | | |
Male | 33 | 15 (45) | | |
Female | 11 | 2 (18) | 0.29 (0.05 to 1.43) | 0.12 |
Febrile days pre-initial IVGG | | | | |
<5 days | 14 | 5 (36) | | |
⩾5 days | 30 | 12 (40) | 0.83 (0.22 to 3.11) | 0.79 |
Febrile days pre-additional IVGG | | | | |
<10 days | 22 | 3 (14) | | |
⩾10 days | 22 | 14 (64) | 11.1 (2.48 to 49.5) | 0.002 |
Febrile days post-additional IVGG | | | | |
<2 days | 28 | 6 (21) | | |
⩾2 days | 16 | 11 (69) | 8.06 (2.01 to 32.3) | 0.003 |
Dose of initial IVGG | | | | |
<1.5 g/kg | 4 | 2 (50) | | |
⩾1.5 g/kg | 40 | 15 (38) | 0.60 (0.08 to 4.72) | 0.63 |
No. of days that initial IVGG was divided over | | | | |
1 or 2 days | 16 | 2 (13) | | |
4 or 5 days | 28 | 15 (54) | 8.06 (1.17 to 41.7) | 0.01 |
Dose of additional IVGG | | | | |
<1.5 g/kg | 13 | 4 (31) | | |
⩾1.5 g/kg | 31 | 13 (42) | 1.62 (0.41 to 6.45) | 0.69 |
No. of days that additional IVGG was divided over | | | | |
1 or 2 days | 26 | 8 (31) | | |
4 or 5 days | 18 | 9 (50) | 2.25 (0.65 to 7.81) | 0.20 |
White blood cell count pre-initial IVGG | | | | |
<11 300/μl | 17 | 5 (29) | | |
⩾11 300/μl | 27 | 12 (44) | 1.92 (0.53 to 6.98) | 0.32 |
CRP pre-initial IVGG | | | | |
<12.2 mg/dl | 24 | 9 (38) | | |
⩾12.2 mg/dl | 20 | 8 (40) | 1.11 (0.33 to 3.78) | 0.87 |
White blood cell count pre-additional IVGG | | | | |
<16 000/μl | 24 | 4 (17) | | |
⩾16 000/μl | 20 | 13 (65) | 9.28 (2.26 to 38.1) | 0.002 |
C reactive protein pre-additional IVGG | | | | |
<9.7 mg/dl | 26 | 6 (23) | | |
⩾9.7 mg/dl | 18 | 11 (61) | 5.24 (1.41 to 19.6) | 0.01 |
White blood cell count post-additional IVGG* | | | | |
<11 300/μl | 22 | 6 (27) | | |
⩾11 300/μl | 17 | 11 (65) | 4.88 (1.25 to 19.2) | 0.02 |
C reactive protein post-additional IVGG* | | | | |
<5.2 mg/dl | 22 | 7 (32) | | |
⩾5.2 mg/dl | 17 | 10 (59) | 3.06 (0.82 to 11.4) | 0.10 |